Clinical Trials Browser

Completed × Pancreatic Neoplasms × Dasatinib × Clear all

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01652976 2021-01-05

FOLFOX-D

Phase 2 Completed

44 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01234935 2018-01-09

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Phase 2 Completed

8 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01395017 2016-04-08

LAPC

Phase 2 Completed

202 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00474812 2015-05-05

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Completed

51 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms